HEMATOLOGY

The newly accepted FDA approval application for betibeglogene autotemcel is supported by 5 studies of the agent across all ages of patients. Eighty-nine percent of evaluable patients achieved transfusion independence.

Ronald S. Go, MD, a hematology oncologist with the Mayo Clinic, discusses treating and diagnosing histiocytic neoplasms, a rare hematologic cancer.

Jeffrey Miller, MD, discusses the background of the Tri-Specific Killer Engager TRICK platform for the activation of natural killer cells for the treatment of refractory tumors, including those that are hematology-based.

Complex challenges have arisen with classifying and treating hematologic malignancies in recent years, according to Jorge E. Cortes, MD.

Rachel B. Salit, MD, discussed the case of a 48-year-old patient with graft-versus-host-disease.

Drs Michael Bishop and John DiPersio comment on clinical implications for the use of ruxolitinib in chronic GVHD and share insights on future directions for GVHD.

Expert hematologist/oncologists consider combination therapy with ROCK and JAK inhibitors for the treatment of chronic GVHD as well as the use of ibrutinib for disease management.

Michael Bishop, MD, and John DiPersio, MD, PhD, discuss pulmonary complications associated with chronic GVHD and the management of cytopenias in patients treated with JAK inhibitors.

Drs Michael Bishop and John DiPersio comment on common challenges in measuring response in chronic GvHD and review clinical implication from the REACH3 trial.

Experts in hematology/oncology review factors to consider when approaching the management of chronic graft-versus-host disease.

During an interview, Yi-Bin Chen, MD, an investigator of the REACH trials, discussed acute and chronic graft-versus-host disease and treatment options.

The trial is designed to evaluate eltanexor monotherapy in high-risk MDS. It is recruiting in 8 separate states.

For older patients with acute lymphoblastic leukemia, traditional chemotherapy approaches have largely failed.

John DiPersio, MD, PhD, and Michael Bishop, MD, discuss third-line treatment options for patients with acute and steroid-refractory GVHD.

John DiPersio, MD, PhD, shares his thoughts on approaching initial therapy for chronic GVHD and early intervention with JAK inhibitors.

Despite the success of implementing maintenance therapy in other leukemias, the key challenge with administering maintenance therapy in acute myeloid leukemia has been identifying an effective drug.

Investigators are looking into newer ways of using hypomethylating agents to treat patients with low-risk and high-risk myelodysplastic syndrome.

In an interview with Targeted Oncology, Annette S. Kim, MD, PhD, discussed the updates to the NCCN guidelines on myeloid/lymphoid neoplasms with eosinophilia, along with how to bring new pathology strategies for these disease into clinical practice.

Michael Bishop, MD, leads the discussion on approaching the first-line management of acute GVHD and the importance of early intervention for patients at risk for the disease.

Expert hematologist-oncologists provide insight on major risk factors for GVHD and associated challenges for treatment.

Three medical oncologists from Florida Cancer Specialists are co-authors on a new integrated safety analysis of umbralisib, used to treat lymphoid malignancies.

Dr John DiPersio discusses an early intervention approach to the management of chronic and acute GVHD.

John DiPersio, MD, PhD, and Michael Bishop, MD, define acute and chronic graft-vs-host disease (GVHD).